Navigation Links
Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
Date:8/19/2007

ong clinical rationale to pursue development of PDX in this setting," said Dr. Horwitz.

Information regarding this study is available at http://www.allos.com or the U.S. government's clinical trials database at http://www.clinicaltrials.gov.

About Cutaneous T-cell Lymphoma

The cutaneous T-cells lymphomas are comprised of a number of non-Hodgkins T-cell lymphomas, including mycosis fungoides and Sezary syndrome, which have their primary manifestations in the skin. According to the Lymphoma Research Foundation, CTCL comprises about 2% to 3% of the estimated 63,000 new cases of non-Hodgkin's lymphoma diagnosed annually.

About PDX (pralatrexate)

PDX is a novel, small molecule chemotherapeutic agent that inhibits dihydrofolate reductase, or DHFR, a folic acid (folate)-dependent enzyme involved in the building of nucleic acid, or DNA, and other processes. PDX was rationally designed for efficient transport into tumor cells via the reduced folate carrier, or RFC-1, and effective intracellular drug retention. We believe these biochemical features, together with preclinical and clinical data in a variety of tumors, suggest that PDX may have a favorable safety and efficacy profile relative to methotrexate and certain other DHFR inhibitors.

About Allos Therapeutics, Inc.

Allos Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer. The company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma. The company is also investigating PDX in patients with non-small cell lung cancer and a range of other lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemotherapeutic agent, for w
'/>"/>

SOURCE Allos Therapeutics, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
2. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
5. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
6. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
11. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014  Actavis plc (NYSE: ... received a complete response letter from the U.S. ... Drug Application (NDA) for the fixed-dose combination (FDC) ... hypertension.   Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... the receipt of a complete response letter, Actavis ...
(Date:12/24/2014)... 2014 Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... products that address unmet medical needs in the ... that on December 24, 2014 it closed its ... Company raised approximately $2.3 million in gross proceeds ... net proceeds from the offering to fund its ...
(Date:12/24/2014)... CRANBURY, N.J. and FARMINGTON, ... Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical ... treatment of diseases with significant unmet medical need ... closed on a private placement of 2,050,000 shares ... to purchase 24,949,325 shares of its common stock.  ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... not same, as study cites obesity as possible cause , , ... development of insulin resistance in older men, but not women, ... diabetes, occurs when the body cannot use insulin properly. As ... obese people are prone to insulin resistance, because excess fat ...
... fusion cuisine is one of,the year,s hottest trends(1). ... international flavors are filling Americans, plates. And because,it ... flavor profiles,it,s no surprise that pork is consumed ... the creators of The Other White Meat(R) campaign ...
... the largest online retailers of diabetic testing supplies launched an ... for people with diabetes , , ... even stronger support system thanks to Diabetic Care Services, one ... The company launched an improved version of its Web site ...
... DIEGO, Dec. 5 Cardium Therapeutics,(NYSE Alternext: CXM) ... New York City,s adoption of procedures designed to ... featured in an,article in The New York ... Therapy,",dated December 4, 2008, reports that New York ...
... #236 , , BETHLEHEM, Pa., ... products and practices , B. Braun Medical Inc. (B. Braun) ... American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20081022/NYW008LOGO ...
... problems, study says , , FRIDAY, Dec. 5 (HealthDay News) -- ... are three times more likely than people without the disease ... according to a British study. , "If you look ... threefold increased risk of acute coronary syndrome, which is a ...
Cached Medicine News:Health News:Vitamin K Slows Insulin Resistance in Older Men 2Health News:Take Taste Buds on a Trip Around the World This Holiday Season 2Health News:Take Taste Buds on a Trip Around the World This Holiday Season 3Health News:Turn to Diabetic Care Services for Personalized Support and Hassle-Free Diabetes Supplies 2Health News:Cardium Reports on New York City's Adoption of Therapeutic Cooling Protocols for Cardiac Arrest Patients 2Health News:Cardium Reports on New York City's Adoption of Therapeutic Cooling Protocols for Cardiac Arrest Patients 3Health News:Cardium Reports on New York City's Adoption of Therapeutic Cooling Protocols for Cardiac Arrest Patients 4Health News:Cardium Reports on New York City's Adoption of Therapeutic Cooling Protocols for Cardiac Arrest Patients 5Health News:Cardium Reports on New York City's Adoption of Therapeutic Cooling Protocols for Cardiac Arrest Patients 6Health News:Cardium Reports on New York City's Adoption of Therapeutic Cooling Protocols for Cardiac Arrest Patients 7Health News:Cardium Reports on New York City's Adoption of Therapeutic Cooling Protocols for Cardiac Arrest Patients 8Health News:Cardium Reports on New York City's Adoption of Therapeutic Cooling Protocols for Cardiac Arrest Patients 9Health News:Be Green with B. Braun: Company Shares Expertise, Environmentally Responsible Products at ASHP 2008 2Health News:Be Green with B. Braun: Company Shares Expertise, Environmentally Responsible Products at ASHP 2008 3Health News:Lung Disease Tied to Increased Risk for Cardiac Events 2
... This BioSafe room is configured specifically ... and chemical analysis. Panels are precision-joined ... easy to wipe down and disinfect. ... double-wall panel design creates strong, rigid ...
... Features hardwall acrylic panels ... frame to form a free-standing ... to Class 10/ISO 3. Optional ... and ionizers are configured to ...
... curtains or parting strip shields ... frame to form a free-standing, ... cleanliness to Class 10/ISO 3. ... lights, and ionizers are configured ...
... cleanroom for biological safety labs (BSL) ... (to Class 10/ISO 3) and easy ... ultra-smooth surfaces that are easy to ... corners simplify cleaning. Unique double-wall panel ...
Medicine Products: